Status:
WITHDRAWN
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)
Lead Sponsor:
Gilead Sciences
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
1-24 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.
Eligibility Criteria
Inclusion
- \<24 months of age
- Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening
Exclusion
- Chronic or congenital heart disease
- Required ventilation or admission to any pediatric Intensive Care Unit
- Inadequate organ function
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01797419
Start Date
May 1 2013
End Date
August 1 2013
Last Update
October 28 2013
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Geelong Hospital
Geelong, Victoria, Australia, 3220
2
Monash Medical Center
Clayton, Australia
3
Queensland Children's Medical Research Unit
Herston, Australia
4
Royal Hobart Hospital
Hobart, Australia